Last reviewed · How we verify

Baraclude tablets — Competitive Intelligence Brief

Baraclude tablets (Baraclude tablets) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nucleoside reverse transcriptase inhibitor (NRTI). Area: Virology / Hepatology.

marketed Nucleoside reverse transcriptase inhibitor (NRTI) Hepatitis B virus reverse transcriptase / HBV polymerase Virology / Hepatology Small molecule Live · refreshed every 30 min

Target snapshot

Baraclude tablets (Baraclude tablets) — Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Baraclude (entecavir) inhibits hepatitis B virus reverse transcriptase, blocking viral replication.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Baraclude tablets TARGET Baraclude tablets Chia Tai Tianqing Pharmaceutical Group Co., Ltd. marketed Nucleoside reverse transcriptase inhibitor (NRTI) Hepatitis B virus reverse transcriptase / HBV polymerase
Placebo & Entecavir Placebo & Entecavir Fu-Sheng Wang marketed Nucleoside reverse transcriptase inhibitor (NRTI) Hepatitis B virus reverse transcriptase / HBV polymerase
entecavir (BARACLUDE®) entecavir (BARACLUDE®) National Taiwan University Hospital marketed Nucleoside reverse transcriptase inhibitor (NRTI) Hepatitis B virus reverse transcriptase / HBV polymerase
blank Baraclude tablets blank Baraclude tablets Chia Tai Tianqing Pharmaceutical Group Co., Ltd. marketed Nucleoside reverse transcriptase inhibitor (NRTI) Hepatitis B virus reverse transcriptase / HBV polymerase
Baraclude Tab.® Baraclude Tab.® Dong-A ST Co., Ltd. marketed Nucleoside reverse transcriptase inhibitor (NRTI) Hepatitis B virus reverse transcriptase / HBV polymerase
entecavir, lamivudine entecavir, lamivudine Asan Medical Center marketed Nucleoside reverse transcriptase inhibitor (NRTI) Hepatitis B virus reverse transcriptase
ZIAGEN® ZIAGEN® ViiV Healthcare marketed Nucleoside reverse transcriptase inhibitor (NRTI) HIV reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nucleoside reverse transcriptase inhibitor (NRTI) class)

  1. French National Agency for Research on AIDS and Viral Hepatitis · 3 drugs in this class
  2. Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 2 drugs in this class
  3. ViiV Healthcare · 2 drugs in this class
  4. Nanfang Hospital, Southern Medical University · 2 drugs in this class
  5. Asan Medical Center · 1 drug in this class
  6. Dong-A ST Co., Ltd. · 1 drug in this class
  7. Bristol-Myers Squibb · 1 drug in this class
  8. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · 1 drug in this class
  9. Fu-Sheng Wang · 1 drug in this class
  10. Avexa · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Baraclude tablets — Competitive Intelligence Brief. https://druglandscape.com/ci/baraclude-tablets. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: